$UNH
UNITEDHEALTH GROUP INC Stock $unh

$unh Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000073176617000016 Filed on May 08, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$48.72B	$44.53B
YoY Change	9.42%	24.53%
Cost Of Revenue	$5.676B	$5.877B
YoY Change	-3.42%	427.56%
Gross Profit	$43.05B	$38.65B
YoY Change	11.38%	11.57%
Gross Profit Margin	88.35%	86.8%
Selling, General & Admin	$7.022B	$6.758B
YoY Change	3.91%	15.84%
% of Gross Profit	16.31%	17.49%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$533.0M	$502.0M
YoY Change	6.18%	32.8%
% of Gross Profit	1.24%	1.3%
Operating Expenses	$7.022B	$6.758B
YoY Change	3.91%	15.84%
Operating Profit	$3.413B	$2.960B
YoY Change	15.3%	12.12%
Interest Expense	$283.0M	$259.0M
YoY Change	9.27%	72.67%
% of Operating Profit	8.29%	8.75%
Other Income/Expense, Net
YoY Change
Pretax Income	$3.130B	$2.701B
YoY Change	15.88%	8.47%
Income Tax	$939.0M	$1.074B
% Of Pretax Income	30.0%	39.76%
Net Earnings	$2.172B	$1.611B
YoY Change	34.82%	14.01%
Net Earnings / Revenue	4.46%	3.62%
Basic Earnings Per Share	$2.28	$1.69
Diluted Earnings Per Share	$2.23	$1.67
COMMON SHARES
Basic Shares Outstanding	954.0M shares	953.0M shares
Diluted Shares Outstanding	975.0M shares	967.0M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$16.14B	$10.60B
Short-Term Investments
Other Short-Term Assets	$2.547B	$3.211B
YoY Change	-20.68%	22.0%
Inventory
Prepaid Expenses
Receivables	$9.595B	$7.777B
Other Receivables	$6.609B	$6.865B
Total Short-Term Assets	$40.99B	$33.75B
YoY Change	21.47%	26.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.329B	$4.976B
YoY Change	27.19%	17.22%
Goodwill	$52.38B	$46.29B
YoY Change	13.14%	41.22%
Intangibles	$8.618B	$8.861B
YoY Change	-2.74%	157.51%
Long-Term Investments	$594.0M	$23.31B
YoY Change	-97.45%	9.99%
Other Assets	$3.085B	$3.084B
YoY Change	0.03%	0.75%
Total Long-Term Assets	$96.17B	$84.11B
YoY Change	14.34%	33.62%
TOTAL ASSETS
Total Short-Term Assets	$40.99B	$33.75B
Total Long-Term Assets	$96.17B	$84.11B
Total Assets	$137.2B	$117.9B
YoY Change	16.38%	31.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.47B	$13.74B
YoY Change	-1.94%	30.63%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$3.502B	$3.702B
YoY Change	-5.4%
Long-Term Debt Due	$7.747B	$6.504B
YoY Change	19.11%	132.53%
Total Short-Term Liabilities	$57.54B	$46.29B
YoY Change	24.32%	32.33%
LONG-TERM LIABILITIES
Long-Term Debt	$26.15B	$27.22B
YoY Change	-3.91%	74.73%
Other Long-Term Liabilities	$2.385B	$1.887B
YoY Change	26.39%	45.71%
Total Long-Term Liabilities	$28.54B	$29.11B
YoY Change	-1.94%	72.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.54B	$46.29B
Total Long-Term Liabilities	$28.54B	$29.11B
Total Liabilities	$91.50B	$80.96B
YoY Change	13.01%	43.58%
SHAREHOLDERS EQUITY
Retained Earnings	$42.52B	$37.96B
YoY Change	12.01%	11.16%
Common Stock	$10.00M	$10.00M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.90B	$35.17B
YoY Change
Total Liabilities & Shareholders Equity	$137.2B	$117.9B
YoY Change	16.38%	31.36%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$2.172B	$1.611B
YoY Change	34.82%	14.01%
Depreciation, Depletion And Amortization	$533.0M	$502.0M
YoY Change	6.18%	32.8%
Cash From Operating Activities	$6.456B	$2.318B
YoY Change	178.52%	2.16%
INVESTING ACTIVITIES
Capital Expenditures	$507.0M	$425.0M
YoY Change	19.29%	13.94%
Acquisitions	$468.0M	$1.697B
YoY Change	-72.42%	195.13%
Other Investing Activities	-$25.00M	-$14.00M
YoY Change	78.57%	-143.75%
Cash From Investing Activities	-$2.289B	-$4.181B
YoY Change	-45.25%	174.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$412.0M	$302.0M
YoY Change	36.42%	-57.1%
Debt Paid & Issued, Net	$1.392B	$601.0M
YoY Change	131.61%	44.47%
Cash From Financing Activities	$1.525B	$1.502B
YoY Change	1.53%	202.82%
NET CHANGE
Cash From Operating Activities	$6.456B	$2.318B
Cash From Investing Activities	-$2.289B	-$4.181B
Cash From Financing Activities	$1.525B	$1.502B
Net Change In Cash	$5.692B	-$361.0M
YoY Change	-1676.73%	-129.11%
FREE CASH FLOW
Cash From Operating Activities	$6.456B	$2.318B
Capital Expenditures	$507.0M	$425.0M
Free Cash Flow	$5.949B	$1.893B
YoY Change	214.26%	-0.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9595000000	USD
CY2016Q4	unh	Aarp Assets Under Management AarpAssetsUnderManagement	3105000000	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000731766
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	963661565	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	UNITEDHEALTH GROUP INC
CY2017Q1	unh	Aarp Assets Under Management AarpAssetsUnderManagement	2886000000	USD
CY2016Q4	unh	Assets Measuredat Fair Valueona Recurring Basisasa Percentageof Total Assetsat Fair Value AssetsMeasuredatFairValueonaRecurringBasisasaPercentageofTotalAssetsatFairValue	1.00
CY2017Q1	unh	Assets Measuredat Fair Valueona Recurring Basisasa Percentageof Total Assetsat Fair Value AssetsMeasuredatFairValueonaRecurringBasisasaPercentageofTotalAssetsatFairValue	1.00
CY2016Q1	unh	Cumulative Effectof New Accounting Pronouncement CumulativeEffectofNewAccountingPronouncement	28000000	USD
CY2016Q4	unh	Investments Amortized Cost InvestmentsAmortizedCost	26859000000	USD
CY2017Q1	unh	Investments Amortized Cost InvestmentsAmortizedCost	28444000000	USD
CY2016Q4	unh	Investments Gross Unrealized Gains InvestmentsGrossUnrealizedGains	145000000	USD
CY2017Q1	unh	Investments Gross Unrealized Gains InvestmentsGrossUnrealizedGains	167000000	USD
CY2016Q4	unh	Investments Gross Unrealized Losses InvestmentsGrossUnrealizedLosses	290000000	USD
CY2017Q1	unh	Investments Gross Unrealized Losses InvestmentsGrossUnrealizedLosses	234000000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13361000000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2681000000	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13473000000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8152000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	6069000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	10041000000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2447000000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1819000000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7000000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9000000	shares
CY2016Q4	us-gaap	Assets Assets	122810000000	USD
CY2017Q1	us-gaap	Assets Assets	137157000000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	33879000000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	40989000000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	39810000000	USD
CY2017Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	46897000000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	92000000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	123000000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	243000000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	192000000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	24330000000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	25772000000	USD
CY2016Q4	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	52000000	USD
CY2017Q1	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	43000000	USD
CY2016Q4	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	47000000	USD
CY2017Q1	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	42000000	USD
CY2016Q4	us-gaap	Available For Sale Equity Securities Amortized Cost Basis AvailableForSaleEquitySecuritiesAmortizedCostBasis	2036000000	USD
CY2017Q1	us-gaap	Available For Sale Equity Securities Amortized Cost Basis AvailableForSaleEquitySecuritiesAmortizedCostBasis	2120000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	6090000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	10049000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	2006000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	1993000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	3291000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	3293000000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	24179000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	25703000000	USD
CY2016Q4	us-gaap	Available For Sale Securities Equity Securities AvailableForSaleSecuritiesEquitySecurities	2041000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Equity Securities AvailableForSaleSecuritiesEquitySecurities	2121000000	USD
CY2017Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	10000	positions
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt	926000000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10923000000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10596000000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10430000000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16142000000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	10430000000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	16142000000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-327000000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5712000000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.500
CY2017Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.625
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	952000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	965000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	952000000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	965000000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	10000000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	10000000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2141000000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2406000000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	16000000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	19000000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	2157000000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	2425000000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5877000000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5676000000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	41567000000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	45310000000	USD
CY2016Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	33022000000	USD
CY2017Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	33491000000	USD
CY2016Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	34728000000	USD
CY2017Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	35300000000	USD
CY2016Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	32770000000	USD
CY2017Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	33210000000	USD
CY2016Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	145000000	USD
CY2017Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-89000000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1968000000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6475000000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2761000000	USD
CY2017Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2894000000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	502000000	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	533000000	USD
CY2016Q1	us-gaap	Dividends Cash DividendsCash	477000000	USD
CY2017Q1	us-gaap	Dividends Cash DividendsCash	596000000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.69
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.28
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.67
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.23
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	34000000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	20000000	USD
CY2017Q1	us-gaap	Equity Method Investments EquityMethodInvestments	594000000	USD
CY2016Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2017Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2017Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2016Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2017Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2016Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2017Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	USD
CY2016Q4	us-gaap	Goodwill Goodwill	47584000000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	52376000000	USD
CY2016Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	493000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	552000000	USD
CY2016Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	1000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	1000000	USD
CY2016Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	0	USD
CY2017Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	0	USD
CY2017Q1	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	120000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount	120000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	111000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	111000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsFairValue	131000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsNetCarryingAmount	130000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	191000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	191000000	USD
CY2016Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	494000000	USD
CY2017Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	553000000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2701000000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	3130000000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1074000000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	939000000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2036000000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	292000000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1110000000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1232000000	USD
CY2016Q1	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	1067000000	USD
CY2017Q1	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	3217000000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-251000000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4496000000	USD
CY2016Q1	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	1368000000	USD
CY2017Q1	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	1024000000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2162000000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	998000000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8541000000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8618000000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	259000000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	283000000	USD
CY2016Q4	us-gaap	Interest Rate Derivative Assets At Fair Value InterestRateDerivativeAssetsAtFairValue	55000000	USD
CY2017Q1	us-gaap	Interest Rate Derivative Assets At Fair Value InterestRateDerivativeAssetsAtFairValue	45000000	USD
CY2016Q4	us-gaap	Interest Rate Derivative Liabilities At Fair Value InterestRateDerivativeLiabilitiesAtFairValue	14000000	USD
CY2017Q1	us-gaap	Interest Rate Derivative Liabilities At Fair Value InterestRateDerivativeLiabilitiesAtFairValue	19000000	USD
CY2016Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	183000000	USD
CY2017Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	222000000	USD
CY2017Q1	us-gaap	Investment Owned Balance Contracts InvestmentOwnedBalanceContracts	27000
CY2016Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	26714000000	USD
CY2017Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	28377000000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	82621000000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	91495000000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122810000000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137157000000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	49252000000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	57543000000	USD
CY2015Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	14330000000	USD
CY2016Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	15823000000	USD
CY2016Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	16391000000	USD
CY2017Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	17650000000	USD
CY2016Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	2524000000	USD
CY2017Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	2519000000	USD
CY2016Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	0	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	76000000	USD
CY2016Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	15797000000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	18742000000	USD
CY2016Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	11140000000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	12154000000	USD
CY2016Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	11600000000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	12500000000	USD
CY2016Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	28430000000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	32079000000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	7193000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	234000000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	7747000000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3085000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	388000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	180000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	530000000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25777000000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	26154000000	USD
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	23868000000	USD
CY2017Q1	us-gaap	Long Term Investments LongTermInvestments	25760000000	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	-97000000	USD
CY2017Q1	us-gaap	Minority Interest MinorityInterest	2092000000	USD
CY2016Q1	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-59000000	USD
CY2017Q1	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	389000000	USD
CY2016Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	8000000	USD
CY2017Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	11000000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1502000000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1525000000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4181000000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2289000000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2318000000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6456000000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	1611000000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	2172000000	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	16000000	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	19000000	USD
CY2016Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	1622000000	USD
CY2017Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	2181000000	USD
CY2017Q1	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	2191000000	USD
CY2017Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2960000000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3413000000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3037000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	35000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	21000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	22000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	13000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	13000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	8000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	260000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	99000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	164000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	67000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	96000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	32000000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10339000000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12198000000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2307000000	USD
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	34811000000	USD
CY2017Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	38938000000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2385000000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6000000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-43000000	USD
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	7499000000	USD
CY2017Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6609000000	USD
CY2016Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
CY2017Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	1860000000	USD
CY2016Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	26937000000	USD
CY2017Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	30896000000	USD
CY2016Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-14000000	USD
CY2017Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-25000000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	500000000	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	682000000	USD
CY2016Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	477000000	USD
CY2017Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	596000000	USD
CY2016Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1697000000	USD
CY2017Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	468000000	USD
CY2016Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5173000000	USD
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3683000000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	425000000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	507000000	USD
CY2016Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	28430000000	USD
CY2017Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	32079000000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1848000000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2547000000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	198000000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270000000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2485000000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1342000000	USD
CY2016Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	978000000	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1326000000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	38177000000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43995000000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56000000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1923000000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	150000000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	189000000	USD
CY2016Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	500000000	USD
CY2016Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-385000000	USD
CY2017Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	682000000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33725000000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35067000000	USD
CY2017Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-495000000	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-285000000	USD
CY2017Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-139000000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2122000000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1018000000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	1627000000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	2191000000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5901000000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6329000000	USD
CY2016Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	2012000000	USD
CY2017Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1667000000	USD
CY2017Q1	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	642000000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	601000000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1392000000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	40945000000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	42521000000	USD
CY2016Q1	us-gaap	Revenues Revenues	44527000000	USD
CY2017Q1	us-gaap	Revenues Revenues	48723000000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6393000000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6129000000	USD
CY2016Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	3140000000	USD
CY2017Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	3434000000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6758000000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7022000000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	157000000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	196000000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	2845000000	USD
CY2017Q1	us-gaap	Short Term Investments ShortTermInvestments	3210000000	USD
CY2016Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	28790000000	USD
CY2017Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	32529000000	USD
CY2016Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-360000000	USD
CY2017Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-450000000	USD
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	14000000	shares
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	21000000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	967000000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	975000000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	953000000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	954000000	shares
CY2017Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the components of the change in medical costs payable for the three months ended March 31: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical costs payable, beginning of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisitions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported medical costs:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(360</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total reported medical costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,430</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical payments:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments for current year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,742</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,797</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments for prior years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,154</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total medical payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,896</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical costs payable, end of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,823</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and revenues, valuation and impairment analysis of goodwill and other intangible assets and valuations of certain investments. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.</font></div></div>

Files In Submission

Name	View Source	Status
0000731766-17-000016-index-headers.html	Edgar Link	pending
0000731766-17-000016-index.html	Edgar Link	pending
0000731766-17-000016.txt	Edgar Link	pending
0000731766-17-000016-xbrl.zip	Edgar Link	pending
directorpicutrea01.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
uhglogo1a01a01a09.jpg	Edgar Link	pending
unh-20170331.xml	Edgar Link	completed
unh-20170331.xsd	Edgar Link	pending
unh-20170331_cal.xml	Edgar Link	unprocessable
unh-20170331_def.xml	Edgar Link	unprocessable
unh-20170331_lab.xml	Edgar Link	unprocessable
unh-20170331_pre.xml	Edgar Link	unprocessable
unh331201710-q.htm	Edgar Link	pending
unhex1013312017.htm	Edgar Link	pending
unhex1213312017.htm	Edgar Link	pending
unhex3113312017.htm	Edgar Link	pending
unhex3213312017.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UNH
UNITEDHEALTH GROUP INC Stock $unh

2017 Q1 Form 10-Q Financial Statement

#000073176617000016 Filed on May 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNH UNITEDHEALTH GROUP INC Stock $unh

2017 Q1 Form 10-Q Financial Statement

#000073176617000016 Filed on May 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNH
UNITEDHEALTH GROUP INC Stock $unh